Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Advances in treatment and prevention of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in children

Pediatric Research (2026)Cite this article

Abstract

In recent years, there has been a significant increase in reported cases of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in pediatric patients, and its standardized treatment and effective prevention have increasingly attracted clinical attention. This article reviews the latest treatment approach for pulmonary thromboembolism complicated by Mycoplasma pneumoniae pneumonia in children, including anticoagulant therapy, systemic thrombolytic therapy, interventional therapy, and surgical therapy. Meanwhile, progress in research on the risk factors of this condition is also reviewed, aiming to provide new directions for future preventive studies.

Impact

  • While several reviews have addressed the clinical characteristics of pulmonary thromboembolism (PTE) associated with Mycoplasma Pneumoniae pneumonia (MPP) in pediatric patients, there remains a lack of comprehensive syntheses focusing specifically on treatment and prevention. This review provides an integrated analysis of the latest evidence on treatment strategies over the past 5 years, facilitating informed clinical decision-making. Moreover, this review is the first to systematically map the studies on the risk factors of PTE induced by MPP, directly informing the directions of future preventive studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Wang, X. et al. Mycoplasma pneumoniae triggers pneumonia epidemic in autumn and winter in Beijing: a multicentre, population-based epidemiological study between 2015 and 2020. Emerg. Microbes Infect. 11, 1508–1517 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sun, Y. et al. Characterizing the epidemiology of Mycoplasma pneumoniae infections in China in 2022-2024: a nationwide cross-sectional study of over 1.6 million cases. Emerg. Microbes Infect. 14, 2482703 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chen, L. et al. Thromboembolic complications of Mycoplasma pneumoniae pneumonia in children. Clin. Respir. J. 17, 187–196 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Liu, J. et al. Mycoplasma pneumoniae pneumonia associated thrombosis at Beijing Children’s hospital. BMC Infect. Dis. 20, 51 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rastogi, R. et al. Incidence, management, and outcomes of pulmonary embolism at tertiary pediatric hospitals in the United States. JACC Adv. 3, 100895 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jin, P., Han, C., Guo, W. & Xu, Y. Mycoplasma pneumoniae pneumonia-associated thromboembolism with plastic bronchitis: a series of five case reports and literature review. Ital. J. Pediatr. 50, 117 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ross, C. et al. Acute management of high-risk and intermediate-risk pulmonary embolism in children: a review. Chest 161, 791–802 (2022).

    Article  PubMed  Google Scholar 

  8. The Respiratory Group, Pediatric Branch of the Chinese Medical Association et al. Evidence-based guideline for the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children. Chin. J. Pediatr. 62, 1137–1144 (2024).

    Google Scholar 

  9. Ahn, J. G. et al. Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis. BMC Infect. Dis. 21, 1003 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tsai, T. A., Tsai, C. K., Kuo, K. C. & Yu, H. R. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J. Microbiol. Immunol. Infect. 54, 557–565 (2021).

    Article  CAS  PubMed  Google Scholar 

  11. Ortel, T. L. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 4, 4693–4738 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Klaassen, I. L. M. et al. Are low-molecular-weight heparins safe and effective in children? A systematic review. Blood Rev. 33, 33–42 (2019).

    Article  CAS  PubMed  Google Scholar 

  13. The Pediatric Professional Committee of the Chinese Medical Education Association et al. Expert consensus on the diagnosis and treatment of pulmonary thromboembolism in children. Chin. J. Appl. Clin. Pediatr. 40, 81–91 (2025).

    Google Scholar 

  14. Monagle, P. et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141, e737S–e801S (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Male, C. et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 7, e18–e27 (2020).

    Article  PubMed  Google Scholar 

  16. Halton, J. et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 8, e22–e33 (2021).

    Article  CAS  PubMed  Google Scholar 

  17. Hassan, E. & Motwani, J. Real world experience of efficacy and safety of rivaroxaban in paediatric venous thromboembolism. Thromb. Res. 221, 92–96 (2023).

    Article  CAS  PubMed  Google Scholar 

  18. Janssen Pharmaceuticals. Product Monograph: Xarelto/rivaroxaban. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215859s000lbl.pdf (2025).

  19. US Food and Drug Administration. Prescribing information: ELIQUIS (apixaban) tablets. 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/202155s039s040lbl.pdf (2025).

  20. US Food and Drug Administration. Prescribing information: Pradaxa (dabigatran etexilate) oral pellets. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214358s000lbl.pdf (2025).

  21. US Food and Drug Administration. Prescribing information: Pradaxa (dabigatran etexilate) capsules. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022512s041lbl.pdf (2025).

  22. Zhang, T. et al. Case report: cardiac multiple thrombus and pulmonary embolism associated with Mycoplasma pneumonia infection in a child. Front. Pediatr. 10, 959218 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  23. Song, S. & Xu, Y. A retrospective study of the clinical characteristics of 9 children with pulmonary embolism associated with Mycoplasma pneumoniae pneumonia. BMC Pediatr. 23, 370 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Cheng, R., Wang, Q., Jiang, L. & Liu, L. M. Pulmonary thromboembolism due to Mycoplasma pneumoniae in children: a case report and literature review. BMC Pediatr. 24, 816 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  25. Xiaoqian, F. & Hemin, L. Successful rivaroxaban and doxycycline therapy for Mycoplasma pneumonia with pulmonary embolism in children: a case report. Front. Pediatr. 13, 1449493 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  26. Zhang, J. et al. Clinical characteristics and therapeutic experience with rivaroxaban in children with Mycoplasma pneumoniae pneumonia associated with pulmonary thromboembolism. Chin. J. Pediatr. 63, 373–378 (2025).

    CAS  Google Scholar 

  27. Monagle, P. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2, 3292–3316 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  28. Goldenberg, N. A. et al. Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the Kids-DOTT randomized clinical trial. JAMA 327, 129–137 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Saleem, S. & Berman, B. Deep vein thrombosis and pulmonary embolism in the setting of Mycoplasma infection. Case Rep. Med. 2020, 8708417 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  30. Chen, S., Ke, S., Vinturache, A., Dong, X. & Ding, G. Pulmonary embolism associated with Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 58, 3605–3608 (2023).

    Article  PubMed  Google Scholar 

  31. Kenet, G., Limperger, V., Shneyder, M. & Nowak-Göttl, U. Risk factors for symptomatic venous and arterial thromboembolism in newborns, children and adolescents-what did we learn within the last 20 years? Blood Cell Mol. Dis. 67, 18–22 (2017).

    Article  Google Scholar 

  32. Stevens, S. M. et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160, 2247–2259 (2021).

    Article  PubMed  Google Scholar 

  33. Tarango, C. & Manco-Johnson, M. J. Pediatric thrombolysis: a practical approach. Front. Pediatr. 5, 260 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  34. Herzog, E. et al. Interventional treatment of pediatric venous thromboembolic disease. Tech. Vasc. Interv. Radiol. 27, 100957 (2024).

    Article  PubMed  Google Scholar 

  35. Alsabri, M. et al. Epidemiology and management of massive, sub-massive, and non-massive pediatric pulmonary embolism: a systematic reviews. BMC Pediatr. 25, 330 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  36. Mishra, A. et al. Comparison of catheter-directed thrombolysis vs systemic thrombolysis in pulmonary embolism: a propensity score match analysis. Chest 152, A1047 (2017).

    Article  Google Scholar 

  37. Alqeeq, B. F. et al. Catheter-directed therapy for pulmonary embolism in pediatrics: a systematic review and meta-analysis. Thromb. J. 23, 4 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  38. Zhu, Q., Pan, T., Bai, Z. & Li, Y. Catheter directed thrombolysis in children with high-risk pulmonary embolism: a case report and literature review. Chin. Pediatr. Emerg. Med. 28, 440–443 (2021).

    Google Scholar 

  39. Goldberg, J. B. et al. Survival and right ventricular function after surgical management of acute pulmonary embolism. J. Am. Coll. Cardiol. 76, 903–911 (2020).

    Article  PubMed  Google Scholar 

  40. Huang, K. et al. Mycoplasma pneumoniae pneumonia complicated with cardiac thrombus and pulmonary embolism: a case report and literature review. J. Clin. Pediatr. 39, 421–424 (2021).

    Google Scholar 

  41. Yang, J. et al. Clinical analysis of 15 cases of severe Mycoplasma pneumoniae pneumonia complicated by cardiac thrombosis in children. Chin. J. Pediatr. 63, 535–540 (2025).

    CAS  Google Scholar 

  42. Sheng, C. Q., Yang, C. F., Ao, Y., Zhao, Z. Y. & Li, Y. M. Mycoplasma pneumoniae pneumonia with pulmonary embolism: a study on pediatric cases in Jilin province of China. Exp. Ther. Med. 21, 201 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Chi, G., Lee, J. J., Memar Montazerin, S. & Marszalek, J. Association of D-dimer with short-term risk of venous thromboembolism in acutely ill medical patients: a systematic review and meta-analysis. Vasc. Med. 27, 478–486 (2022).

    Article  CAS  PubMed  Google Scholar 

  44. Zheng, Y. et al. The level of D-dimer is positively correlated with the severity of Mycoplasma pneumoniae pneumonia in children. Front. Cell. Infect. Microbiol. 11, 687391 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Huang, X. et al. Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia. BMC Infect. Dis. 21, 14 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Han, C. et al. Analysis of the risk factors and clinical features of Mycoplasma pneumoniae pneumonia with embolism in children: a retrospective study. Ital. J. Pediatr. 48, 153 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  47. Guan, Y. et al. Development and evaluation of a nomogram for predicting pulmonary embolism in children with severe Mycoplasma pneumoniae pneumonia. Pediatr. Pulmonol. 60, e71046 (2025).

    Article  PubMed  Google Scholar 

  48. Gu, H., Li, B., Han, Y., Yang, S. & Wang, X. Risk factors for suspected pulmonary embolism in children: complication of Mycoplasma pneumoniae pneumonia. Eur. J. Radiol. 176, 111474 (2024).

    Article  PubMed  Google Scholar 

  49. Hou, J. et al. Pulmonary embolism in children with Mycoplasma pneumonia: can it be predicted? Eur. J. Clin. Microbiol. Infect. Dis. 44, 393–403 (2025).

    Article  PubMed  Google Scholar 

  50. Zhang, X. et al. Clinical characteristics and risk factors of pulmonary embolism with Mycoplasma pneumoniae pneumonia in children. Sci. Rep. 14, 24043 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Yu, Y., Jin, X., Zhang, X. & Shen, Y. Pulmonary thrombotic complication of Mycoplasma pneumoniae pneumonia in Chinese children: clinical feature and risk factor analysis. Pediatr. Infect. Dis. J. 43, 505–510 (2024).

    Article  PubMed  Google Scholar 

  52. Wang, C. et al. Characteristics and outcomes of Mycoplasma pneumoniae pneumonia associated with pulmonary embolism and necrotizing pneumonia in children. Infect. Drug Resist. 17, 1961–1969 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Kim, K. et al. Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis. JAMA Netw. Open 5, e2220949 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  54. Fu, Y. et al. Clinical characteristics of 14 pediatric Mycoplasma pneumoniae pneumonia associated thrombosis: a retrospective study. BMC Cardiovasc. Disord. 23, 1 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Brown, S. M. et al. Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors. Pediatr. Pulmonol. 43, 200–202 (2008).

    Article  PubMed  Google Scholar 

  56. Graw-Panzer, K. D., Verma, S., Rao, S., Miller, S. T. & Lee, H. Venous thrombosis and pulmonary embolism in a child with pneumonia due to Mycoplasma pneumoniae. J. Natl. Med. Assoc. 101, 956–958 (2009).

    PubMed  Google Scholar 

  57. Hahn, D. W., Atkinson, C. E. & Le, M. Multiple anatomic sites of infarction in a pediatric patient with M. pneumoniae infection, a case report. BMC Pediatr. 21, 372 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  58. Jiang, T. T. et al. The clinical significance of macrolide resistance in pediatric Mycoplasma pneumoniae infection during COVID-19 pandemic. Front. Cell. Infect. Microbiol. 13, 1181402 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Lanata, M. M. et al. Macrolide-resistant Mycoplasma pneumoniae infections in children, Ohio, USA. Emerg. Infect. Dis. 27, 1588–1597 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Huang, Z., Zhang, B. & Cheng, B. Mycoplasma pneumoniae pneumonia complicated with pulmonary embolism: a systematic analysis of published case reports. Int. J. Clin. Exp. Med. 9, 11574–11581 (2016).

    Google Scholar 

  61. Alsabri, M. et al. Systematic review of case series and case reports on pediatric pulmonary embolism. J. Med. Case Rep. 19, 76 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The study was supported by the National Natural Science Foundation of China (8230021174) and the “Qingdao Outstanding Young Medical Talent Development Program”.

Author information

Authors and Affiliations

  1. Department of Pediatrics, The Affiliated Hospital of Qingdao University, Qingdao, China

    Yang Hu, Hui Ma & Renzheng Guan

Authors
  1. Yang Hu
    View author publications

    Search author on:PubMed Google Scholar

  2. Hui Ma
    View author publications

    Search author on:PubMed Google Scholar

  3. Renzheng Guan
    View author publications

    Search author on:PubMed Google Scholar

Contributions

Yang Hu: drafting the article. Hui Ma: revising the article critically for important intellectual content. Renzheng Guan: substantial contribution to conception and final approval of the version to be published.

Corresponding author

Correspondence to Renzheng Guan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

There are no prior publications or submissions with any overlapping information. The article has not been presented as an abstract or poster before the submission.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, Y., Ma, H. & Guan, R. Advances in treatment and prevention of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in children. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-04794-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41390-026-04794-y

Search

Advanced search

Quick links